Key facts
- This page summarizes Ola Soderquist's Form 4 filing for BIOXYTRAN, INC (BIXT).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 13 May 2022, 12:37.
Ola Soderquist - 11 May 2022 Form 4 Insider Report for BIOXYTRAN, INC (BIXT)
- Reporting relationship
- CFO, 10%+ Owner
- Issuer ticker
- BIXT
- Reported as of
- 11 May 2022
- Net transaction value
- -$36,000
- SEC form
- 4
- Accepted by SEC
- 13 May 2022, 12:37:08 UTC
- Prior SEC filing
- 07 Apr 2022
- Next SEC filing
- 08 Feb 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Ola Soderquist
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Ola Soderquist filed Form 4 for BIOXYTRAN, INC (BIXT) on 13 May 2022.
Change
- Previous filing in this sequence was filed on 07 Apr 2022.
- Current net transaction value: -$36,000.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
BIXT
transaction
Derivative
Warrants
Gift
- Transaction value
- $36,000
- Shares
- -100,000
- Change %
- -100%
- Price
- $0.3600
- Shares after
- 0
- Date
- 11 May 2022
- Ownership
- by NDPD Pharma, Inc.
- Underlying class
- Common
- Underlying amount
- 100,000
- Exercise price
- $2.00
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The warrant agreement includes Provisions for dilutive issuance and cash-less exercise